申请人:GLAXO GROUP LIMITED
公开号:EP0266899A2
公开(公告)日:1988-05-11
The invention relates to compounds of formula (I)
wherein R¹ represents a hydrogen atom or a group selected from C1-10 alkyl, C3-6 alkenyl, C3-10 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, phenyl, or phenyl C1-3alkyl, -CO₂R¹⁰, -COR¹⁰, -CONR¹⁰R¹¹ or -SO₂R¹⁰ (wherein R¹⁰ and R¹¹, which may be the same or different , each represents a hydrogen atom, a C1-6 alkyl or C3-7 cycloalkyl group, or a phenyl or phenylC1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C1-4 alkyl, C1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R¹⁰ does not represent a hydrogen atom when R¹ represents a group -CO₂R¹⁰ or -SO₂R¹⁰);
R₂ represents a hydrogen atom or a C1-6 alkyl, C3-6 alkenyl, C3-7 cycloalkyl, phenyl or phenyl C1-3 alkyl group;
R₃ and R₄, which may be the same of different, each represents a hydrogen atom or a C1-6 alkyl group;
One of the groups represented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C1-6 alkyl, C1-6 hydroxyalkyl, C3-7 cycloalkyl, C2-6 alkenyl, phenyl or phenyl C1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C1-6 alkyl group; and
Q represents a hydrogen or a halogen atom, or a hydroxy, C1-4 alkoxy, phenyl C1-3 alkoxy or C1-6 alkyl group or a group -NR⁸R⁹ or -CONR⁸R⁹ wherein R⁸ and R⁹, which may be the same or different, each represents a hydrogen atom or a C1-4 alkyl or C3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring;
and physiologically acceptable salts and solvates thereof.
The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
本发明涉及式 (I) 的化合物
其中 R¹ 代表氢原子或选自 C1-10 烷基、C3-6 烯基、C3-10 炔基、C3-7 环烷基、C3-7 环烷基 C1-4 烷基、苯基或苯基 C1-3 烷基、-CO₂R¹⁰、-COR¹⁰、-CONR¹⁰R¹¹ 或-SO₂R¹⁰(其中 R¹⁰ 和 R¹¹可以相同或不同,各自代表一个氢原子、C1-6烷基或C3-7环烷基,或苯基或苯基C1-4烷基,其中苯基任选被一个或多个C1-4烷基、C1-4烷氧基或羟基或卤素原子取代,但当R¹代表基团-CO₂R¹⁰或-SO₂R¹⁰时,R¹₂不代表氢原子);
R₂ 代表氢原子或 C1-6 烷基、C3-6 烯基、C3-7 环烷基、苯基或苯基 C1-3 烷基;
R₃ 和 R₄ 可以相同或不同,各自代表氢原子或 C1-6 烷基;
R⁵、R⁶ 和 R⁷ 所代表的基团之一是氢原子或 C1-6 烷基、C1-6 羟烷基、C3-7 环烷基、C2-6 烯基、苯基或苯基 C1-3 烷基,另外两个基团(可以相同或不同)各自代表氢原子或 C1-6 烷基;以及
Q 代表氢原子或卤素原子,或羟基、C1-4 烷氧基、苯基 C1-3 烷氧基或 C1-6 烷基,或基团 -NR⁸R⁹ 或 -CONR⁸R⁹ 其中 R⁸ 和 R⁹ 可以相同或不同,各自代表氢原子或 C1-4 烷基或 C3-4 烯基,或与所连接的氮原子一起形成饱和的 5-7 分子环;
及其生理上可接受的盐和溶剂。
这些化合物是 5-HT 在 5-HT₃ 受体上的强效选择性拮抗剂,可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。